Brought to you by 
Series A round brings in CHF21mm for Telormedix
04 Nov 2008
Executive Summary
Telormedix SA (immunomodulators for cancer and viral diseases) raised CHF21mm ($19mm) through its Series A round. Seed investor Aravis Venture led and was joined by Proquest Investments, BSI SA, Nextech Venture, and Generali Insurance Group. Partners from Aravis and Proquest have taken seats on the company's board.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series A round brings in CHF21mm for Telormedix
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice